Elanco Animal Health announced that the U.S. Food and Drug Administration granted Emergency Use Authorization for its product Credelio CAT (lotilaner) to treat New World screwworm infestations in cats. The authorization was issued on November 21 2025, the same day the company disclosed the decision, marking a regulatory milestone for the company’s flea‑ and tick‑control portfolio.
The New World screwworm (Cochliomyia hominivorax) is a parasitic fly whose larvae can cause severe tissue damage in mammals. Recent detections of the fly near the U.S.–Mexico border have raised concerns about a potential spread into the United States. Credelio CAT, already approved for flea and tick control, now offers veterinarians and cat owners a ready‑now treatment option should the fly enter the country.
By expanding the use of an existing, widely distributed product, Elanco gains a first‑mover advantage in a niche market that could grow as the threat expands. The EUA also reinforces the company’s strategy of rapidly addressing emerging animal‑health risks, potentially opening new revenue streams and strengthening its reputation for proactive product development.
Elanco’s leadership highlighted the importance of swift regulatory action to protect animal health. The company views the EUA as a key step in its broader commitment to respond to emerging parasitic threats and to provide veterinarians with effective tools for disease prevention and treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.